Orexigen's MysimbaTM approved by European Commission for treatment of obesity
Orexigen announced the EC has granted marketing authorization for Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for management of weight in adult patients. This authorization applies to all 28 EU member states. March 26, 2015